Cargando…
Nasal spray (Zavegepant) for migraines: a mini-review
Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research being conducted in the field of anti-migraine therapies, including the discovery of Zavegepant for the treatment of acute migraine attacks. Zavegepant is a novel, first-in-c...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289569/ https://www.ncbi.nlm.nih.gov/pubmed/37363553 http://dx.doi.org/10.1097/MS9.0000000000000843 |
_version_ | 1785062309085839360 |
---|---|
author | Larik, Muhammad Omar Iftekhar, Muhammad Ashhal Syed, Bilal Ulhassan Ansari, Omema Ansari, Mozaena |
author_facet | Larik, Muhammad Omar Iftekhar, Muhammad Ashhal Syed, Bilal Ulhassan Ansari, Omema Ansari, Mozaena |
author_sort | Larik, Muhammad Omar |
collection | PubMed |
description | Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research being conducted in the field of anti-migraine therapies, including the discovery of Zavegepant for the treatment of acute migraine attacks. Zavegepant is a novel, first-in-class, intranasally administered calcitonin gene-related peptide (CGRP) receptor antagonist that has recently been approved for use in acute migraine attacks. Recent randomized controlled trials comparing Zavegepant with a placebo have demonstrated favorable results with respect to primary endpoints, as well as a desirable safety profile. The current first-line therapy consists of oral triptans, which are associated with lower efficacy, weaker safety profile, and an unsatisfactory preference rate among patients. Moreover, the intranasal method of administration is a characteristic advantage of Zavegepant, as patients suffering from acute migraine attacks cannot easily ingest oral medication, due to severe nausea and vomiting. In this mini-review, the efficacy and safety of Zavegepant will be compared with those of alternative treatments available for migraines, including oral triptans, intranasal triptans, and other CGRP antagonists currently available in the market. With currently available research, Zavegepant holds superiority over other forms of treatment and can be included in the current treatment guidelines for migraine attacks. However, further research is necessary to effectively assess Zavegepant’s long-term efficacy, safety, tolerability, and drug–drug interactions. |
format | Online Article Text |
id | pubmed-10289569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-102895692023-06-24 Nasal spray (Zavegepant) for migraines: a mini-review Larik, Muhammad Omar Iftekhar, Muhammad Ashhal Syed, Bilal Ulhassan Ansari, Omema Ansari, Mozaena Ann Med Surg (Lond) Review Articles Neurological disorders, especially migraines, pose a significant global burden. This has driven the recent innovative research being conducted in the field of anti-migraine therapies, including the discovery of Zavegepant for the treatment of acute migraine attacks. Zavegepant is a novel, first-in-class, intranasally administered calcitonin gene-related peptide (CGRP) receptor antagonist that has recently been approved for use in acute migraine attacks. Recent randomized controlled trials comparing Zavegepant with a placebo have demonstrated favorable results with respect to primary endpoints, as well as a desirable safety profile. The current first-line therapy consists of oral triptans, which are associated with lower efficacy, weaker safety profile, and an unsatisfactory preference rate among patients. Moreover, the intranasal method of administration is a characteristic advantage of Zavegepant, as patients suffering from acute migraine attacks cannot easily ingest oral medication, due to severe nausea and vomiting. In this mini-review, the efficacy and safety of Zavegepant will be compared with those of alternative treatments available for migraines, including oral triptans, intranasal triptans, and other CGRP antagonists currently available in the market. With currently available research, Zavegepant holds superiority over other forms of treatment and can be included in the current treatment guidelines for migraine attacks. However, further research is necessary to effectively assess Zavegepant’s long-term efficacy, safety, tolerability, and drug–drug interactions. Lippincott Williams & Wilkins 2023-05-15 /pmc/articles/PMC10289569/ /pubmed/37363553 http://dx.doi.org/10.1097/MS9.0000000000000843 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Review Articles Larik, Muhammad Omar Iftekhar, Muhammad Ashhal Syed, Bilal Ulhassan Ansari, Omema Ansari, Mozaena Nasal spray (Zavegepant) for migraines: a mini-review |
title | Nasal spray (Zavegepant) for migraines: a mini-review |
title_full | Nasal spray (Zavegepant) for migraines: a mini-review |
title_fullStr | Nasal spray (Zavegepant) for migraines: a mini-review |
title_full_unstemmed | Nasal spray (Zavegepant) for migraines: a mini-review |
title_short | Nasal spray (Zavegepant) for migraines: a mini-review |
title_sort | nasal spray (zavegepant) for migraines: a mini-review |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289569/ https://www.ncbi.nlm.nih.gov/pubmed/37363553 http://dx.doi.org/10.1097/MS9.0000000000000843 |
work_keys_str_mv | AT larikmuhammadomar nasalsprayzavegepantformigrainesaminireview AT iftekharmuhammadashhal nasalsprayzavegepantformigrainesaminireview AT syedbilalulhassan nasalsprayzavegepantformigrainesaminireview AT ansariomema nasalsprayzavegepantformigrainesaminireview AT ansarimozaena nasalsprayzavegepantformigrainesaminireview |